Sugi Predict

Sugi Predict / Targets / AGPAT2

AGPAT2

1-acyl-sn-glycerol-3-phosphate acyltransferase beta · O15120 · AGPAT2 on Sugi Atlas →

8,656 patent compounds predicted against AGPAT2, 4,035 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3136695 SCHEMBL3136695 0.55 17/20
SCHEMBL3128167 SCHEMBL3128167 0.52 17/20
SCHEMBL3118001 SCHEMBL3118001 0.51 17/20
SCHEMBL3141124 SCHEMBL3141124 0.50 16/20
SCHEMBL3146883 SCHEMBL3146883 0.54 15/20
SCHEMBL2622384 SCHEMBL2622384 0.88 14/20
SCHEMBL2631865 SCHEMBL2631865 0.81 13/20
SCHEMBL2310806 SCHEMBL2310806 0.69 13/20
SCHEMBL1856664 SCHEMBL1856664 0.51 13/20
SCHEMBL929779 SCHEMBL929779 0.47 13/20
SCHEMBL2622388 SCHEMBL2622388 0.88 12/20
SCHEMBL2242010 SCHEMBL2242010 0.69 12/20
SCHEMBL2410666 SCHEMBL2410666 0.69 12/20
SCHEMBL3116847 SCHEMBL3116847 0.50 12/20
SCHEMBL2622393 SCHEMBL2622393 0.74 11/20
SCHEMBL1935325 SCHEMBL1935325 0.59 11/20
SCHEMBL1915457 SCHEMBL1915457 0.54 11/20
SCHEMBL2785782 SCHEMBL2785782 0.52 11/20
SCHEMBL3241054 SCHEMBL3241054 0.51 11/20
SCHEMBL1033197 SCHEMBL1033197 0.49 11/20

Clinical trials — most relevant to AGPAT2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Omega 3 and Ischemic Stroke; Fish Oil as an Option PHASE4UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate PHASE2/PHASE3WITHDRAWN
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC PHASE1/PHASE2UNKNOWN
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris PHASE1/PHASE2UNKNOWN
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
RCDP Natural History Study nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism nanCOMPLETED
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Genetic Determinants:Low HDL, High Triglycerides, Obesity nanCOMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
Systemic Biomarkers of Brain Injury From Hyperammonemia nanRECRUITING
11C-Acetate PET/CT Non-FDG-Avid Tumors nanUNKNOWN
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study. nanRECRUITING
Intraumbilical Amino Acids and Glucose Supplementation Via Port by Severe IUGR in Human Fetuses nanCOMPLETED
Choline to Improve Malnutrition and Enhance Cognition nanRECRUITING
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease. nanUNKNOWN
Genetic Origin of Lipid Disorders nanUNKNOWN
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes nanRECRUITING
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED
Effects of Lipids on Gastric Emptying, Satiety Hormones, and Appetite in Severe Overweight nanCOMPLETED
Plasma Mannose Associated Parameter Levels in Nondiabetic Coronary Artery Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AGPAT2 binder may also engage these)

ProteinNameSimilarity
Q8K3K7 — 0.981 Q8K3K7 →
LPCAT1 Lysophosphatidylcholine acyltransferase 1 0.963 landscape →
Q1HAQ0 — 0.960 Q1HAQ0 →
Q3TFD2 — 0.959 Q3TFD2 →
NOX5 NADPH oxidase 5 0.950 landscape →
ALG1 Chitobiosyldiphosphodolichol beta-mannosyltransferase 0.949 landscape →
Q60714 — 0.949 Q60714 →
Q5R7A2 — 0.949 Q5R7A2 →
SLC27A1 Long-chain fatty acid transport protein 1 0.947 landscape →
Q9D0Z3 — 0.946 Q9D0Z3 →
D3ZLY0 — 0.946 D3ZLY0 →
Q70VZ8 — 0.946 Q70VZ8 →
P97849 — 0.945 P97849 →
Q9QZC8 — 0.945 Q9QZC8 →
DGAT2 Diacylglycerol O-acyltransferase 2 0.945 landscape →
P25409 — 0.945 P25409 →
Q5M7F4 — 0.945 Q5M7F4 →
Q4R3Y4 — 0.944 Q4R3Y4 →
Q3T0A0 — 0.944 Q3T0A0 →
Q80W94 — 0.944 Q80W94 →
Q3KPP4 — 0.944 Q3KPP4 →
Q6P1M0 — 0.943 Q6P1M0 →
Q3ZKN0 — 0.943 Q3ZKN0 →
Q921Q3 — 0.943 Q921Q3 →
Q924S1 — 0.943 Q924S1 →
P24298 — 0.943 P24298 →
A7MBI7 — 0.943 A7MBI7 →
Q3T0R4 — 0.942 Q3T0R4 →
Q5H879 — 0.942 Q5H879 →
Q2TBP5 — 0.942 Q2TBP5 →